Loading
CytomX Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Jones Elaine V, was filed 31 Mar 2023.
CytomX Therapeutics, Inc.: what insiders have been doing
CytomX Therapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 22 October 2026, 13 filings were filed, from 6 insiders.
There is no open-market purchase to report; the filings show 6 sales worth €1.5M by 4 insiders. McCarthy Sean A. filed the largest sale, €664k, on 19 March 2026.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 13 filings in twelve months, the company is quieter than the median of 24 filings across the 3,169 companies we follow on the same exchange. Since 2016, the database holds 2 purchases and 165 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 76.2 m USD and net income of -17.4 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at UCB. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
343
Thresholds
n/a
Buy Volume
€88,872
2 ops. · all time
Sell Volume
€51M
165 ops. · all time
Who traded when
BuySaleChristopher Ogden5 sales
Sean A. McCarthy4 sales
Marcia Belvin3 sales
Yu-Waye Chu2 sales
Lloyd A. Rowland1 sale
Since the insiders bought
- +39.6%Entry US$1.54 · Close at T+365 US$2.15
- -28.2%Entry US$9.89 · Close at T+365 US$7.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate CytomX Therapeutics, Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$12.25.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 25,361 of 26,250 companies
12.9
score / 100
Value18
Quality8
FCF yld-14%
Earn yld-3.3%
EV/EBITDA·
ROE-38%
Gross mgn·
Net mgn-23%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.40
Analyst consensus
8 analystsStrong buy
US$6.00Target US$12.25(+410%)US$16.00
Income statement
RevenueUS$76.2M
EBITDA-US$21M-28% margin
Net income-US$17.4M-22.8% margin
Valuation
PER (forward)-5.1x
P/Book1.7x
Beta2.20
Balance sheet & cash
Market capUS$523M
Total debtUS$4.2M
Free Cash Flow-US$75.8M
Debt / Equity2%
Profitability & ownership
ROE-37.8%
ROA-19.6%
% insiders0.6%
% institutions104.5%
Last declaration on 16 October 2026
Declarations343 total
101,793 shares@ US$1.595.4% of flowCommon StockSEC:0001610717-26-000442:0
100,000 shares0Common StockSEC:0001610717-26-000351:0
1,624 shares@ US$3.053.3% of flowCommon StockSEC:0001610717-26-000229:0
21,279 shares@ US$6.42398.2% of flowCommon StockSEC:0001610717-26-000125:0
31,492 shares@ US$6.42381.3% of flowCommon StockSEC:0001610717-26-000123:0
118,969 shares@ US$6.42332.0% of flowCommon StockSEC:0001610717-26-000124:0
19,323 shares@ US$6.42385.7% of flowCommon StockSEC:0001610717-26-000122:0
20,000 shares0Common StockSEC:0001610717-26-000043:0
75,000 shares0Common StockSEC:0001610717-26-000042:0
60,000 shares0Common StockSEC:0001610717-26-000041:0
210,000 shares0Common StockSEC:0001610717-26-000039:0
90,000 shares0Common StockSEC:0001610717-26-000040:0
101,793 shares@ US$4.537719.4% of flowClass A Common StockSEC:0001610717-25-000372:0
37,500 shares0Common StockSEC:0001610717-25-000236:1
55,511 shares@ US$2.691.4% of flowCommon StockSEC:0001610717-25-000234:1
10,614 shares@ US$2.6915.7% of flowCommon StockSEC:0001610717-25-000236:2
13,884 shares@ US$2.6912.5% of flowCommon StockSEC:0001610717-25-000235:1
37,500 shares0Common StockSEC:0001610717-25-000235:0
150,000 shares0Common StockSEC:0001610717-25-000234:0
1,641 shares@ US$2.95033.3% of flowCommon StockSEC:0001610717-25-000236:0
8,551 shares@ US$0.5993.7% of flowCommon StockSEC:0001610717-25-000085:0
19,512 shares@ US$0.5994.9% of flowCommon StockSEC:0001610717-25-000082:0
4,025 shares@ US$0.5991.8% of flowCommon StockSEC:0001610717-25-000084:0
10,203 shares@ US$0.59922.7% of flowCommon StockSEC:0001610717-25-000083:0
37,656 shares@ US$0.5991.0% of flowCommon StockSEC:0001610717-25-000086:0
25 of 343 declarations
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States, with a clear focus on oncology and, more specifically, conditionally activated biologics. The company traces its operating history back to February 2008, when its predecessor entity commenced operations, and its executive headquarters are located in South San Francisco, California, a major biotechnology cluster. CytomX has built its identity around the proprietary PROBODY® platform, which is designed to keep therapeutic biologics masked until they are activated in the tumor microenvironment, with the goal of improving tumor selectivity and reducing systemic toxicity.
From an industry perspective, CytomX remains a clinical-stage company rather than a commercial-stage pharmaceutical group. Its business model combines internal pipeline development with strategic partnerships that help validate the platform and offset development costs. The core technology has been applied across several therapeutic modalities, including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. The most closely watched programs include varsetatug masetecan, formerly CX-2051, a masked EpCAM-directed ADC, and CX-801, a PROBODY interferon alpha-2b candidate being evaluated in combination with KEYTRUDA® in melanoma.
Read moreShow less
CytomX occupies a differentiated niche in precision oncology. Its competitive edge lies in the idea of localizing activity to the tumor while limiting exposure in healthy tissue, which could support a better therapeutic window if the science continues to translate in human studies. That said, this is still a high-risk development story: the company does not yet have a broad commercial product portfolio, and its value depends heavily on clinical execution, regulatory progress, and financing discipline.
A key part of CytomX’s market position is its collaboration network. The company has longstanding research relationships with major biopharma players including Amgen, Astellas, Bristol Myers Squibb, Moderna, and Regeneron. These partnerships support platform credibility, provide external validation, and can generate milestone and collaboration revenue, while also reducing sole reliance on any single internal program.
Recent updates have been important. In 2026, CytomX reported positive phase 1 dose-expansion data for varsetatug masetecan in advanced colorectal cancer and said it expected FDA interactions mid-year to align on a potential registrational trial design. The company also indicated that initial combination data for CX-801 with KEYTRUDA® in melanoma were expected later in 2026. For investors, CytomX is therefore best viewed as a speculative NASDAQ-listed oncology biotech in the United States, supported by a differentiated proprietary platform but still exposed to substantial clinical, regulatory, and capital-markets risk.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
